Related Experiment Videos
Combination therapy for advanced resistant Hodgkin's disease
Lancet (London, England)
|December 20, 1975
Summary
This study shows that the C.V.B. drug combination (C.C.N.U., vinblastine, and bleomycin) effectively treats advanced Hodgkin
Area of Science:
- Oncology
- Pharmacology
Background:
- Advanced Hodgkin's disease (H.D.) often becomes resistant to standard chemotherapy.
- Effective salvage treatment options are crucial for patients with refractory H.D.
Purpose of the Study:
- To evaluate the efficacy and tolerability of a C.C.N.U., vinblastine, and bleomycin (C.V.B.) combination regimen.
- To assess the response rates in patients with advanced Hodgkin's disease resistant to prior therapies.
Main Methods:
- Thirty-nine patients with advanced, drug-resistant H.D. received C.V.B. chemotherapy.
- Treatment involved C.C.N.U. (lomustine), vinblastine, and bleomycin administered on a cyclical basis.
Main Results:
- An overall response rate of 85% was observed, with 25% achieving complete remission (C.R.).
- C.V.B. demonstrated manageable toxicity, with myelosuppression being the primary concern.
- 54% of patients could receive C.V.B. every 4 weeks, indicating good tolerability for dose intensification.
Conclusions:
- The C.V.B. regimen is an effective salvage therapy for advanced Hodgkin's disease refractory to standard treatments.
- Combination chemotherapy with C.V.B. may offer advantages over single-agent therapies in this patient population.